About X-Ceptor Therapeutics
X-Ceptor Therapeutics is a company based in San Diego (United States) founded in 1999 was acquired by Exelixis in September 2004. X-Ceptor Therapeutics operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of X-Ceptor Therapeutics
Investors in X-Ceptor Therapeutics
X-Ceptor Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Exelixis, Ligand Pharmaceuticals and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm
|
Locked | Locked | Locked | |
|
Multiple investment strategies are pursued by this hedge fund.
|
Locked | Locked | Locked | |
|
Pharmaceutical drugs are manufactured and developed in the United States.
|
Locked | Locked | Locked |
Investor details for X-Ceptor Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by X-Ceptor Therapeutics
Investment portfolio details for X-Ceptor Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - X-Ceptor Therapeutics
Detailed financials for X-Ceptor Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
X-Ceptor Therapeutics Comparisons
Peer comparison for X-Ceptor Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of X-Ceptor Therapeutics
X-Ceptor Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
Detailed competitors of X-Ceptor Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on X-Ceptor Therapeutics
Complete news archive for X-Ceptor Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about X-Ceptor Therapeutics
X-Ceptor Therapeutics was founded in 1999.
X-Ceptor Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
X-Ceptor Therapeutics was founded in 1999 in San Diego, United States, and operated in the biotechnology sector. Small molecule therapeutics were developed to modulate nuclear receptors linked to cholesterol metabolism and cardiovascular conditions. A reverse endocrinology method was employed to validate targets, establish disease proof-of-concept, and advance preclinical candidates. The company was acquired by Exelixis in September 2004 for 22.3 million in cash and stock.
X-Ceptor Therapeutics's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
X-Ceptor Therapeutics has 4 investors. Key investors include Exelixis, Ligand Pharmaceuticals, Farallon Capital Management, and Gimv.